Format

Send to

Choose Destination
Hepatol Int. 2016 Mar;10(2):267-76. doi: 10.1007/s12072-015-9670-9. Epub 2015 Dec 22.

Non-invasive assessment of portal hypertension and liver fibrosis using contrast-enhanced ultrasonography.

Author information

1
Department of Gastroenterology and Nephrology, Chiba University Graduate School of Medicine, 1-8-1, Inohana, Chuou-ku, Chiba, 260-8670, Japan. maru-cib@umin.ac.jp.
2
Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt.
3
Department of Gastroenterology and Nephrology, Chiba University Graduate School of Medicine, 1-8-1, Inohana, Chuou-ku, Chiba, 260-8670, Japan.
4
Department of Gastroenterology & Hepatology, Ganga Ram Institute for Postgraduate Medical Education & Research (GRIPMER), Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, 110 060, India.
5
Department of Gastroenterology, GB Pant Hospital, New Delhi, India.
6
GI/Liver division, GIT Endoscopy Unit, University of Benha, Banha, Egypt.
7
Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, UP, 226014, India.
8
Department of Internal Medicine, Hepatobiliary Division, Cipto Mangunkusumo Hospital, University of Indonesia, Jawa Barat, Indonesia.
9
Yamanashi Hospitals (Central and Kita) Organization, 1-1-1 Fujimi, Kofu-shi, Yamanashi, 400-8506, Japan.

Abstract

Portal hypertension and hepatic fibrosis are key pathophysiologies with major manifestations in cirrhosis. Although the degree of portal pressure and hepatic fibrosis are pivotal parameters, both are determined using invasive procedures. Ultrasound (US) is a simple and non-invasive technique that is available for use worldwide in the abdominal field. Because of its safety and easy of use, contrast-enhanced US is one of the most frequently used tools in the management of liver tumors for the detection and characterization of lesions, assessment of malignancy grade, and evaluation of therapeutic effects. This wide range of applications drives the practical use of contrast-enhanced US for evaluation of the severity of portal hypertension and hepatic fibrosis. The present article reviews the recent progress in contrast-enhanced US for the assessment of portal hypertension and hepatic fibrosis.

KEYWORDS:

Cirrhosis; Contrast agent; Fibrosis; Liver; Portal hemodynamics; Ultrasound

PMID:
26696585
DOI:
10.1007/s12072-015-9670-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center